Phase II Study of Weekly Amrubicin in Patients with Refractory or Relapsed Small Cell Lung Cancer (CJLSG1103)
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2019
Price : $35 *
At a glance
- Drugs Amrubicin (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 05 Dec 2018 Status changed from active, no longer recruiting to completed.
- 30 Nov 2015 Planned End Date changed to 30 Nov 2017 as reported by University Hospital Medical Information Network - Japan.
- 30 Nov 2015 Status changed from suspended to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.